• Research and Resources for Collaboration

  • Network with Adult Sickle Cell Providers

  • Patient Care Resources

  • Education on Clinical Management and Research Opportunities

The Sickle Cell Adult Provider Network (SCAPN)

The Sickle Cell Adult Provider Network (SCAPN) was established in 2002 with a mission to establish and support an interactive network for healthcare providers and investigators who serve adults with sickle cell disease.  This was the first, and remains the only, national organization that offers a home for healthcare professionals from multiple disciplines who focus on adult-oriented research, clinical care, provider education/training, mentorship and advocacy in sickle cell disease.

News

Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients With Sickle Cell Disease Using Altemia Capsules

Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the completion of enrollment of our clinical trial evaluating AltemiaTM, an oral therapy for pediatric patients with Sickle Cell Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, multi-center study to evaluate the efficacy and safety of AltemiaTM in pediatric patients aged 5-17 years old. This trial is conducted under US IND 125274.

"The completion of enrollment in this study represents an important milestone for SPCI and our lead program for SCA and SCD," said Dr. Fred Sancilio, President and Chief Executive Officer of SPCI. "We are very encouraged by the high retention rate and adherence to treatment seen thus far in the study.  This study will further our understanding of the impact of AltemiaTM on Sickle Cell Disease.”

Adrian L. Rabinowicz, M.D, SPCI’s Chief Medical Officer, stated, "The faster than expected enrollment in this study highlights the intense interest and enthusiasm of the investigators, their staffs, as well as the patients and their families in achieving this important step for our development program. We look forward to reporting top-line results from the study early Q4 this year."

For more information about the SCOT Trial, please visit https://clinicaltrials.gov/ct2/show/NCT02973360.

For more information about AltemiaTM, please visit Altemia4sicklecell.com.

About Sickle Cell Disease

Sickle Cell Disease (SCD) and Sickle Cell Anemia (SCA) are a group of genetic disorders that result in dysfunctional hemoglobin and a depletion of certain fatty acids in the membrane of red and white blood cells. These abnormalities increase the red and white blood cells tendency to adhere to each other, which results in episodic occlusions of blood vessels, reperfusion damage, and excruciating pain. Ultimately, many children develop end organ damage and strokes. There are approximately 100,000 cases of SCD in the United States and millions outside of the United States.  Treatment options are limited.

About Sancilio Pharmaceuticals Company, Inc.

Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies® (ALT®) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT® platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT® platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT® platform, we make use of, and license rights to, our proprietary ALT® platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services. More information is available at Sancilio.com.

Contacts
Sancilio Pharmaceuticals Company, Inc.
Marc Wolff, 561-847-2302
Executive Vice President & Chief Financial Officer

 

 

 

 

 

 

 

Events

National Heart Lung and Blood Institute (NHLBI) Clinical Research Meeting - Bethesda, MD - August 14 - 16, 2017

4th Annual SCDAA Walk with the Stars - August 26, 2017 - Baltimore, MD - www.sicklecellnationalwalk.org

Duke School of Nursing Sickle Cell Disease Conference - Duke University - Durham, NC - October 6-7, 2017

Sickle Cell Disease Association of America (SCDAA) National Convention - Atlanta, Ga. - October 26 -28, 2017

11th Annual Sickle Cell in Focus - Kingston, Jamaica - October 26-27, 2017

3rd Annual Sickle Cell Symposium - Carolinas Healthcare System - Concord, NC - October 28, 2017

American Society of Hematology - 59th Annual Meeting - Atlanta, Ga. - December 9 -12, 2017

 

 

 

 

 

 

 

 

  • UPDATE YOUR PROFILE

    Please take a moment to update your Profile

  • Having Technical Issues?

    If you encounter problems trying to log in to the website, please email us at support@scapn.net and let us know. We're here to help!

  • NEXT SCAPN MEETING

    National Heart Lung & Blood Institute (NHLBI)

    Sickle Cell Disease Clinical Research Meeting

    August 14 - 16, 2017

    SCAPN Symposium on August 16, 2017 - Chronic Pain in Sickle Cell Disease - 8:00a - 12:00 noon

    Reception and Board meeting to be held August 15, 2017 at the Doubletree by Hilton Bethesda Hotel - 8120 Wisconsin, Bethesda, MD - 5:30p.m.

     

     

     

     

  • Welcome to SCAPN.net

    We are excited to launch our new website!  A big thank you to the Doris Duke Foundation.  We are now a 501(c)3 organization that facilitates Research, Networking and Resources for Health Care Providers of Sickle Cell Adults!  We welcome you to visit the site and become interactive with us.

    • Feedback on the web site
    • Joining SCAPN
    • Donations
    • Meeting Details
    • Blog
  • JOIN OUR EMAIL LIST

    Click here to become a member and stay informed of all the upcoming news and events.   SCAPN is a 501(c)3 and all donations are tax deductible.